AGC Biologics develops and manufactures Lenti and Retro viral vectors. Our ready-to-use platform capabilities are built on cell factories (up to 48L) and bioreactors (up to 200L) using adherent processes, designed entirely in-house. Our quality systems, GMP manufacturing scale and regulatory qualification allow us to meet both clinical and commercial demand. Moreover, our scale down capabilities provide flexible and cost-effective solutions for process development and pre-clinical studies. Since we perform more than 100 analytical tests in-house, AGC Biologics reduces overall turnaround time. With experience manufacturing three commercial products, we are the only Cell & Gene Therapy (C>) CDMO that has brought its own product to the market (Zalmoxis®).
©2020 AGC Biologics. All Rights Reserved. Website Privacy Policy